Characterization of two novel BRCA1 germ-line mutations involving splice donor sites

Genetic Testing

Volumn 8, Issue 2, 2004, Pages 133-138

  Brose, M S ^a   Volpe, P ^a   Paul, K ^a   Stopfer, J E ^a   Colligon, T A ^a   Calzone, K A ^a   Weber, Barbara L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; MESSENGER RNA;

ARTICLE; GENE MUTATION; HUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA PROCESSING;

BASE SEQUENCE; BRCA1 PROTEIN; BREAST NEOPLASMS; EXONS; FEMALE; GERM-LINE MUTATION; HUMANS; MOLECULAR SEQUENCE DATA; OVARIAN NEOPLASMS; RNA SPLICE SITES;

EID: 4143085918     PISSN: 10906576     EISSN: None     Source Type: Journal    
DOI: 10.1089/1090657041797347     Document Type: Article

References (23)

1. BERGTHORSSON, J.T., JONASDOTTIR, A., JOHANNESDOTTIR, G., ARASON, A., EGILSSON, V., GAYTHER, S., BORG, A., HAKANSON, S., INGVARSSON, S., and BARKARDOTTIR, R.B. (1998). Identification of a novel splice-site mutation of the BRCA1 gene in two breast cancer families: screening reveals low frequency in Icelandic breast cancer patients. Hum. Mutat. Suppl 1, S195-S197.
2. CLAES, K., MACHACKOVA, E., DE VOS, M., POPPE, B., DE PAEPE, A., and MESSIAEN, L. (1999). Mutation analysis of the BRCA1 and BRCA2 genes in the Belgian patient population and identification of a Belgian founder mutation BRCA1 IVS5 + 3A > G. Dis. Markers 15, 69-73.
3. COUCH, F.J., DESHANO, M.L., BLACKWOOD, M.A., CALZONE, K., STOPFER, J., CAMPEAU, L., GANGULY, A., REBBECK, T., and WEBER, B.L. (1997). BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer [see comments]. N. Engl. J. Med. 336, 1409-1415.
4. DOMCHEK, S.M., EISEN, A., CALZONE, K., STOPFER, J., BLACKWOOD, A., and WEBER, B.L. (2003). Application of breast cancer risk prediction models in clinical practice. J. Clin. Oncol. 21, 593-601.
5. GRANN, V.R., JACOBSON, J.S., WHANG, W., HERSHMAN, D., HEITJAN, D.F., ANTMAN, K.H., and NEUGUT, A.I. (2000). Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis. Cancer J. Sci. Am. 6, 13-20.
6. HALL, J.M., LEE, M.K., NEWMAN, B., MORROW, J.E., ANDERSON, L.A., HUEY, B., and KING, M.C. (1990). Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250, 1684-1689.
7. HARTIKAINEN, J.M., PIRSKANEN, M.M., ARFFMAN, A.H., RISTONMAA, U.K., and MANNERMAA, A.J. (2000). A Finnish BRCA1 exon 12 4216-2nt A to G splice acceptor site mutation causes aberrant splicing and frameshift, leading to protein truncation. Hum. Mutat. 15, 120.
8. HOFFMAN, J.D., HALLAM, S.E., VENNE, V.L., LYON, E., and WARD, K. (1998). Implications of a novel cryptic splice site in the BRCA1 gene. Am. J. Med. Genet. 80, 140-144.
9. KRAWCZAK, M., REISS, J., and COOPER, D.N. (1992). The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences. Hum. Genet. 90, 41-54.
10. LEWIN, B. (1994). Genes V. Oxford University Press, New York, pp. 914.
11. LIU, W., QIAN, C., and FRANCKE, U. (1997). Silent mutation induces exon skipping of fibrillin-1 gene in Marfan syndrome. Nature Genet. 16, 328-329.
12. LIU, H.X., ZHANG, M., and KRAINER, A.R. (1998). Identification of functional exonic splicing enhancer motifs recognized by individual SR proteins. Genes Dev. 12, 1998-2012.
13. LIU, H.X., CHEW, S.L., CARTEGNI, L., ZHANG, M.Q., and KRAINER, A.R. (2000). Exonic splicing enhancer motif recognized by human SC35 under splicing conditions. Mol. Cell. Biol. 20, 1063-1071.
14. LIU, H.X., CARTEGNI, L., ZHANG, M.Q., and KRAINER, A.R. (2001). A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. Nature Genet. 27, 55-58.
15. LYNCH, H.T., SNYDER, C.L., LYNCH, J.F., RILEY, B.D., and RUBINSTEIN, W.S. (2003). Hereditary breast-ovarian cancer at the bedside: role of the medical oncologist. J. Clin. Oncol. 21, 740-753.
16. MAZOYER, S., PUGET, N., PERRIN-VIDOZ, L., LYNCH, H.T., SEROVA-SINILNIKOVA, O.M., and LENOIR, G.M. (1998). A BRCA1 nonsense mutation causes exon skipping [letter]. Am. J. Hum. Genet. 62, 713-715.
17. MIKI, Y., SWENSEN, J., SHATTUCK-EIDENS, D., FUTREAL, P.A., HARSHMAN, K., TAVTIGIAN, S., LIU, Q., COCHRAN, C., BENNETT, L.M., and DING, W. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266, 66-71.
18. PUGET, N., STOPPA-LYONNET, D., SINILNIKOVA, O.M., PAGES, S., LYNCH, H.T., LENOIR, G.T., and MAZOYER, S. (1999). Screening for genomic rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions. Cancer Res. 59, 455-461.
19. PYNE, M.T., PRUSS, D., WARD, B.E., and SCHOLL, T. (1999). A characterization of genetic variants in BRCA1 intron 8 identifies a mutation and a polymorphism. Mutat. Res. 406, 101-107.
20. SCHOLL, T., PYNE, M.T., RUSSO, D., and WARD, B.E. (1999). BRCA1 IVS16+6T → C is a deleterious mutation that creates an aberrant transcript by activating a cryptic splice donor site. Am. J. Med. Genet. 85, 113-116.
21. UNGER, M., NATHANSON, L., ANTIN-OZERKIS, D., CALZONE, K., LENOIR, G., MAZOYER, S., and WEBER B. (2000). Screening for genomic rearrangements in breast and ovarian cancer families identifies BRCA1 mutations previously missed by CSGE or sequencing. Am. J. Human Genet. 67(4), 84-50.
22. WOOSTER, R., and WEBER, B.L. (2003). Breast and ovarian cancer. N. Engl. J. Med. 348, 2339-2347.
23. XU, C.F., CHAMBERS, J.A., NICOLAI, H., BROWN, M.A., HUJEIRAT, Y., MOHAMMED, S., HODGSON, S., KELSELL, D.P., SPURR, N.K., BISHOP, D.T., and SOLOMON, E. (1997). Mutations and alternative splicing of the BRCA1 gene in UK breast/ovarian cancer families. Genes, Chromosomes & Cancer 18, 102-110.